Peel

Our Peel drug delivery technology is a drug-containing cream which, once applied to a patient's skin, forms a white pliable layer that releases drug into the skin. The Peel technology allows drug delivery to continue until the product dries, after which drug transfer from the formulation stops. Peel based products can be applied over contoured parts of the body and left on for periods from 20 to 60 minutes, depending on the desired effect. After the desired effect is achieved, the Peel product can be easily peeled from the skin. This drug delivery technology is well-suited for drugs that require a single, short-term application, such as local anesthetics applied before a painful procedure and for uneven, irregular or contoured surfaces.

We have developed our Pliaglis™ product using our proprietary Peel technology.

We believe our phase-changing cream (Peel) technology may have several benefits compared to traditional patches, creams, gels and ointments, including:

  • Controlled Drug Delivery: Conventional creams, ointments and gels do not allow for controlled drug delivery because they are vulnerable to unintended removal by contact with clothing, objects or people and dosing levels vary depending on the thickness or volume applied and the frequency of application. We believe Peel and DuraPeel™ technologies are capable of delivering drugs to areas covered by the product, regionally in tissues near where the product is placed or systemically throughout the blood stream. Peel and DuraPeel™ based formulations create a pliable layer that remains adhered to the skin and maintains drug delivery for desired treatment periods of up to 12 hours.
  • Increased Patient Compliance: Many topical creams require frequent dosing to achieve the intended therapeutic outcome. The frequent dosing requirements can lead to low patient compliance. Because of its ability to sustain prolonged drug delivery periods and to protect against unintentional removal, we believe that DuraPeel™ products may improve patient compliance, which may improve treatment outcome.
  • Application to Large and Irregular Skin Surfaces: The rigidity, size and shape of traditional transdermal patches limit their application to relatively flat skin surfaces. For example, the most commonly used topical local anesthetic preparation may not be suitable for application on all areas of the body because it does not adhere to the application site, which can lead to side effects such as running into the eyes. Peel and DuraPeel™ formulations dispense as a cream that quickly forms a pliable layer that adheres to any intact skin surface.